Sunmax Biotechnology Co Ltd Total Liabilities
Sunmax Biotechnology Co Ltd total liabilities. Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has total liabilities worth NT$454.35 Million TWD (≈ $14.31 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4728 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sunmax Biotechnology Co Ltd (2015–2024)
Total liabilities of Sunmax Biotechnology Co Ltd from 2015 to 2024. This chart illustrates how Sunmax Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Sunmax Biotechnology Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Sunmax Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sapphire Foods India Limited
NSE:SAPPHIRE
|
India | Rs20.39 Billion |
|
Shanghai Yct Electronics Group Co.Ltd
SHE:301099
|
China | CN¥2.54 Billion |
|
Suqian Unitech Corp. Ltd. Cl A
SHG:603065
|
China | CN¥1.60 Billion |
|
Anhui Korrun Co Ltd
SHE:300577
|
China | CN¥3.66 Billion |
|
Hainan Shennong Technology Co Ltd
SHE:300189
|
China | CN¥398.78 Million |
|
Beijing Utour International Travel Service Co Ltd
SHE:002707
|
China | CN¥1.71 Billion |
|
Charter Hall Social Infrastructure REIT
AU:CQE
|
Australia | AU$829.70 Million |
|
CERES POWER HLDGS
F:CFJ
|
Germany | €38.15 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Sunmax Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4728 asset base.
Liquidity & Leverage Metrics
Sunmax Biotechnology Co Ltd Total Liabilities Ratios Explained
Sunmax Biotechnology Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunmax Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual total liabilities of Sunmax Biotechnology Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$337.82 Million ≈ $10.64 Million |
-53.91% |
| 2023-12-31 | NT$732.99 Million ≈ $23.09 Million |
+56.62% |
| 2022-12-31 | NT$468.00 Million ≈ $14.74 Million |
+1.64% |
| 2021-12-31 | NT$460.44 Million ≈ $14.51 Million |
-3.12% |
| 2020-12-31 | NT$475.27 Million ≈ $14.97 Million |
+9.05% |
| 2019-12-31 | NT$435.82 Million ≈ $13.73 Million |
+296.62% |
| 2018-12-31 | NT$109.88 Million ≈ $3.46 Million |
+24.56% |
| 2017-12-31 | NT$88.22 Million ≈ $2.78 Million |
+109.06% |
| 2016-12-31 | NT$42.20 Million ≈ $1.33 Million |
-4.81% |
| 2015-12-31 | NT$44.33 Million ≈ $1.40 Million |
-- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.